

CardiologyRounds™

www.cardiologyrounds.org

AS PRESENTED IN THE ROUNDS OF THE CARDIOVASCULAR DIVISION
OF BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MASSACHUSETTS

Prediction of Coronary Heart Disease Events Part 2: The Contribution of Lifestyle Factors and New Issues

By PETER W. F. WILSON, M.D.

Part 1 of this topic, in the last issue of *Cardiology Rounds*, presented traditional risk factors such as age, gender, cholesterol, blood pressure, smoking, and diabetes and the part they play in predicting coronary heart disease (CHD). In Part 2, the focus is on lifestyle factors (eg, nutrition, physical activity, and obesity) and their contribution to the development of CHD. Other issues that can influence multivariate CHD risk assessment are also discussed such as lifetime risk, inflammatory markers, newer lipid biomarkers, the metabolic syndrome and insulin resistance, genetics, subclinical cardiovascular disease, and kidney disease.

Lifestyle aspects that underlie risk factors

Nutrition, physical activity, and obesity are key lifestyle and environmental features that generally underlie the development of risk factors. Prevention programs often emphasize the importance of these features. For example, greater dietary intake of cholesterol and saturated fat has been related to higher cholesterol levels in several populations.^{1,2} Finland, the region with the highest mean levels of cholesterol in the 1970s, enacted countrywide programs to improve the diet. As a result, the proportion of adults in that country with blood cholesterol levels >250 mg/dL declined from 16% to 3% of the population by the 1990s.³ On the other hand, cholesterol levels have diminished modestly in the U.S. population over the past 2 decades and the average cholesterol in adults is approximately 204 mg/dL.⁴

There is great interest in popular diets, but long-term vascular disease outcome data are generally not available and observational data continue to be the mainstay of nutritional guidelines for the overall consumption of calories, fat, and carbohydrates. Dietary cholesterol guidelines promulgated by expert committees⁴⁸ now recommend consumption of a variety of foods, including fruits, vegetables, grains, and that a healthy body weight, desirable cholesterol level in the blood, and desirable blood pressure (BP) levels are all important.⁵

Increased oxidation has been proposed as an important contributor to atherosclerosis and led to an interest in nutrients that have anti-oxidant properties.⁶ Vitamins B, C, and E have been studied the most, with several observational studies suggesting that greater intake of these vitamins in regular food or as supplements has favorable effects on cardiovascular risk.^{7,8} However,



BRIGHAM AND
WOMEN'S HOSPITAL



HARVARD
MEDICAL SCHOOL
TEACHING AFFILIATE

Cardiovascular Division (Clinical)

Michelle Albert, MD	Richard Lee, MD
Elliott Antman, MD	Eldrin Lewis, MD
Donald S. Baim, MD	James Liao, MD
Kenneth Baughman, MD	Peter Libby, MD
Joshua Beckman, MD	(Division Chief)
Gavin Blake, MD	Leonard Lilly, MD
Charles M. Blatt, MD	Bernard Lown, MD
Eugene Braunwald, MD	William Maisel, MD
Christopher Cannon, MD	Thomas Michel, MD, PhD
Ming Hui Chen, MD	David Morrow, MD
Michael Chin, MD, PhD	Karen Moulton, MD
Mark Creager, MD	Gilbert Mudge, MD
Victor Dzau, MD	Anju Nohria, MD
Elazer Edelman, MD, PhD	Patrick O'Gara, MD
Andrew Eisenhauer, MD	Marc A. Pfeffer, MD, PhD
Laurence Epstein, MD	(Editor)
James Fang, MD	Jorge Plutzky, MD
Mark Feinberg, MD	Jeffrey Popma, MD
Daniel Forman, MD	Shmuel Ravid, MD
Jonas Galper, MD, PhD	Frederic Resnic, MD
Peter Ganz, MD	Paul Ridker, MD
J. Michael Gaziano, MD	Thomas Rocco, MD
Marie Gerhard-Herman, MD	Campbell Rogers, MD
Robert Giugliano, MD	Maria Rupnick, MD, PhD
Michael Givertz, MD	Arthur Sasahara, MD
Samuel Z. Goldhaber, MD	S. Dinakar Satti, MD
Thomas B. Graboys, MD	Jay Schneider, MD
Howard Hartley, MD	Christine Seidman, MD
Carolyn Ho, MD	Andrew Selwyn, MD
Mukesh Jain, MD	Daniel Simon, MD
John Jarcho, MD	Laurence Sloss, MD
Paula Johnson, MD	Kyoko Soejima, MD
Ralph Kelly, MD	Regina Sohn, MD
Scott Kinlay, MD	Scott Solomon, MD
Jamil Kirdar, MD	Lynne Stevenson, MD
James Kirshenbaum, MD	William Stevenson, MD
Gideon Koren, MD	Peter Stone, MD
Richard Kuntz, MD	Michael Sweeney, MD
Raymond Kwong, MD	Frederick Welt, MD
Michael J. Landzberg, MD	Justina Wu, MD

Brigham and Women's Hospital

Fax: (617) 732-5291 Website: www.heartdoc.org

The editorial content of *Cardiology Rounds* is determined solely by the Cardiovascular Division of Brigham and Women's Hospital. This publication is made possible by an educational grant.

**Cardiology Rounds is approved
by the Harvard Medical School
Department of Continuing Education
to offer continuing education credit**

recent controlled clinical trials of supplemental vitamins have generally not demonstrated reductions in risk of cardiovascular disease (CVD).⁹⁻¹¹

Alcohol intake in the range of >2 drinks/day in men and >1 drink/day in women has consistently been related to a reduced risk of CHD.¹² Favorable effects on high-density lipoprotein (HDL) cholesterol levels are thought to be important in exerting this effect, as well as anti-inflammatory and anti-platelet effects. Greater alcohol intake is not without hazards, however, and a greater risk of gastrointestinal bleeding, hemorrhagic stroke, accidents, suicide, and cirrhosis may be associated with increased intake.¹³

A more active lifestyle generally leads to lower risk for CHD. Early studies investigated occupations and risk for CVD, but more recent research has concentrated on leisure-time physical activity. Data from the Harvard Alumni Study showed that greater exercise was inversely related to risk of fatal and nonfatal myocardial infarction (MI) over an 8-year interval.¹⁴ This result and others showed that physical activity in middle-aged adults was important in reducing CVD risk.¹⁵ There is, however, an increased risk for sudden cardiac death during or following exercise in persons who generally perform little exercise, but adverse events are uncommon.^{16,17}


Greater fitness that has been documented by longer exercise treadmill times has been related to reduced risk for CHD in men and women.¹⁸ Persons in the lowest quintile of fitness experienced the highest CHD event rates and even modest degrees of fitness were related to lower risk of CHD in studies of middle-aged men and women.

Obesity

Excess adiposity has been defined by the World Health Organization and 2 general measures are used: body mass index (BMI, which is calculated using body weight in kilograms divided by height in meters squared); and abdominal girth (greatest circumference of the abdomen when a subject is standing).¹⁹ A person is considered overweight when the BMI is 25-29.9 kg/m² and obese when the BMI is >30 kg/m². Increased abdominal adiposity is defined as >90 cm for women and >100 cm for men.

The prevalence of obesity has increased dramatically over the course of the past 30 years in the United States.²⁰ Data from U.S. surveys from 1960 to 2000 have shown that the prevalence of obesity more than doubled, from 10% to 27% in men and from 16% to 34% in women.

Figure 1: Lifetime risk of CHD – Framingham men and women²⁴



Correspondingly, the prevalence of overweight has also increased and it is now estimated that >50% of American adults are either overweight or obese.^{19,49} A similar worrisome pattern is occurring in adolescents.

Obesity contributes to the development of several CHD risk factors, especially hypertension, diabetes mellitus, low HDL cholesterol, elevated triglycerides, and elevated levels of inflammatory markers. Weight gain, even relatively modest increases, during the adult years is highly related to developing a greater risk factor burden.²¹ Obesity augments the effects of traditional risk factors and accounts for approximately 23% of CHD in men and 15% in women in long-term analyses of Framingham data.²² When obesity is considered as an additional risk factor for the development of CHD over and above the traditional risk factors, there is no added benefit in knowing the level of obesity. The absence of an effect potentially has many sources as adiposity is highly related to BP, low HDL cholesterol, diabetes mellitus, age, and inflammatory markers.

Newer issues for multivariable CHD risk assessment

Lifetime risk

The lifetime risk of CHD is highly related to gender and age. At age 40 years, the Framingham men experienced a 49% risk of developing CHD (angina pectoris, MI, or CHD death) prior to death. The lifetime incidence was lower in older persons who had never experienced CHD and, at age 70 years, the lifetime risk for CHD in men was 35% (Figure 1). The lifetime risks for CHD in women were lower at each age in comparisons to the men. Overall, the lifetime risk for CHD was approximately 40% in men and 30% in women.²³ In contrast, the lifetime

risk for developing breast cancer in women is approximately 10%, a rate that is much lower than a woman's lifetime risk for CHD. Lifetime risk estimates extend the traditional 5- to 10-year CHD risk estimates to a distant horizon, but this approach has not been incorporated into CHD risk estimating strategies that are in common usage in the United States and Europe.

Inflammation

A variety of factors related to hematologic, endothelial, or inflammatory processes have been studied regarding their relationship to CHD. Early studies investigated leukocyte count and these were followed by fibrinogen determinations. In a meta-analysis, patients with fibrinogen levels in the top third had a doubling of risk for initial and recurrent CVD events.²⁴ A European investigation assessed the relationships between recurrent CHD and levels of fibrinogen, von Willebrand factor antigen, t-PA antigen, and C-reactive protein (CRP) in persons with angina pectoris. Each of these markers was highly related to a greater risk of subsequent CHD in categorical analyses that used quintiles of each factor.²⁵ Subsequent research in a large number of studies has shown that inflammatory markers, especially CRP, are highly related to increased risk of atherosclerotic events,²⁶ including initial and recurrent CVD, as well as stroke.⁷⁰⁻⁷³ Therefore, measurement of inflammatory markers, specifically high sensitivity C-reactive protein (hsCRP), is now considered a reasonable adjunct to the major risk factors to further assess absolute risk for coronary disease primary prevention.³¹

Blood levels of the amino acid homocysteine have been studied for their relationship to CVD risk. In the early 1990s, investigations demonstrated that a lower intake of B vitamins (folate, vitamin B₆, vitamin B₁₂) was related to greater concentrations of homocysteine.³² Persons with higher homocysteine levels experienced greater risk for CVD; however, reports of this relationship were more frequent in earlier studies than in more recent investigations.^{33,34} Folate fortification of cereals and grains was undertaken in the United States during the late 1990s to reduce the risk of neural tube defects during pregnancy and this appears to have reduced the frequency of elevated homocysteine levels in the free living population.³⁵ Additional folate intake from supplementary vitamins and multivitamins may be contributing to the reduced importance of homocysteine as a CVD risk factor. However, homocysteine may still be an important contributor to greater CHD risk in specific situations, such as in persons with impaired kidney function.^{36,37}

Newer lipid biomarkers

A large variety of lipoprotein particles have been identified and several techniques are available for assessing their density, diameter, electrophoretic characteristics, and nuclear magnetic resonance properties. Initially, the low-density lipoprotein (LDL) particles received the most attention, as apolipoprotein B is present in the LDL fraction. Research interest has spread to investigating the role of all particle groups as newer methods have allowed rapid assessment of the numbers and concentrations of lipoprotein particles.³⁸⁻⁴⁰ The smaller denser LDL particles may be associated with greater risk, but the added usefulness of these measurements for the assessment of CVD risk in prospective studies is not assured at this time.^{41,42}

Lipoprotein (a) [Lp(a)] is an accepted determinant of CVD risk and this particle includes an LDL moiety that is linked to a protein chain that bears homology to plasminogen. The length of the apo (a) protein varies and is heritable. A variety of methods have been undertaken to assay Lp(a),⁴³ but standardization has been difficult because the particle varies in composition from person to person.⁴⁴ Levels of Lp(a) are higher in Africans and African Americans than in whites.⁴⁵ In African populations, the particle concentrations follow a normal statistical distribution, but Lp(a) levels are lower and the distribution is skewed in whites. Lp(a) has generally been shown to be a CVD risk factor, especially at the higher concentrations (>30 mg/dL) in whites.⁴⁶ Routine screening for Lp(a) levels has been recommended for persons with premature CVD that is not explained by conventional risk factor levels.^{47,48}

Metabolic syndrome and insulin resistance

Several CVD risk factors occur at a greater frequency than expected and insulin resistance is thought to account for a clustering of traits, especially higher BP, impaired fasting glucose, increased triglycerides, decreased HDL cholesterol, and greater abdominal adiposity. The presence of ≥ 3 of these 5 abnormalities has been named the "metabolic syndrome," and some of the criteria are sex-specific.⁵⁰

The metabolic syndrome is present in approximately 24% of American adults according to U.S. survey data from the early 1990s and the prevalence is highly related to age, ranging from 7% in persons aged 20-29 years to 43% in persons aged 60-69 years.⁵¹ The presence of the metabolic syndrome in adults has been shown to confer an increased risk of diabetes mellitus, CHD, and CVD death.⁵²⁻⁵⁴

Genetics

Determining the contribution of genetic abnormalities and variants in common genes to the risk of atherosclerotic disease is an intensely active area of investigation.^{55,56} Diseases such as familial hypercholesterolemia have been shown to have several potential causes and, taken together, they probably account for approximately 5% of the case burden of persons with MI.⁵⁷ The different alleles of apolipoprotein E have been related to cholesterol and triglyceride levels in young adults, the risk of CVD in middle age, and dementia in older age.⁵⁸⁻⁶⁰ The apolipoprotein E4 allele is present in approximately 24% of the population and is associated with a relative risk for CHD of 1.5. This has led to the realization that this gene variant accounts for approximately 10% to 15% of CHD.^{59,61} Variants of several other genes, including the angiotensin-converting enzyme, lipoprotein (a),⁴⁴ cholesterol ester transfer protein, hepatic lipase, and methylene tetrahydrofolate reductase [MTHFR] (related to folate and homocysteine metabolism), are some examples of candidate genes being studied for their relationship to metabolic factors and CHD risk and the list of candidates is growing rapidly. It is likely that genetic information will be used to assess the potential of developing risk factors in middle-age and to evaluate differential responses to environmental and pharmacologic interventions.

Subclinical cardiovascular disease

Modern techniques can provide an assessment of subclinical vascular disease in smaller arteries. The carotid arteries have been studied with B-mode ultrasound and, more recently, with magnetic resonance imaging. Greater carotid stenoses in older persons have been correlated with the burden of smoking, high BP, and higher cholesterol levels during the adult years,⁶² and increased intima media thickening of the carotid arteries in the elderly has been shown to be predictive of the subsequent development of CVD.⁶³ The usefulness of these testing modalities is limited by the need for accurate measurements and trained sonographers.

Over the past few years, scanning the coronary arteries for the presence of calcification has been proposed as a useful strategy for identifying persons at high risk for the development of clinical CVD.^{64,65} Data from less potentially biased groups without self-referral are limited at the present, but large investiga-

tions, such as the Multi-Ethnic Study of Atherosclerosis, should help provide a critical assessment of the added usefulness of these newer screening modalities in non-selected population cohorts.⁶⁶

Kidney disease

In the 1980s, proteinuria was shown to be related to an increased risk of CHD⁶⁷ and more recent research has focused on microalbuminuria (> 30 mg/gm urinary creatinine) as a marker of renal impairment in persons with hypertension or diabetes mellitus. Modest decrements in estimated glomerular filtration rate and the presence of microalbuminuria have been shown to be important predictors of decline in renal function and the development of CVD.^{68,69} Assessment of albumin excretion is now recommended at regular intervals for persons with diabetes mellitus or hypertension.

Long-term treatment of hypertension and type 2 diabetes mellitus has led to the extension of life, but chronic kidney failure may occur. These 2 diseases are now the most common diagnoses for persons who need to start chronic dialysis.⁷⁰ Once renal failure has developed, the prognosis is quite poor since atherosclerosis appears to enter an accelerated phase and death from CVD or from cardiac failure is quite common.

Summary

The summation of risk factors, using modern research methods, provides a quantitative estimate of an individual's odds of manifesting CHD in the future. Even more important, these factors provide a rationale and target for therapies and lifestyle modifications to substantially reduce, but probably not eliminate, the absolute risk for future atherosclerotic events in westernized societies.

References


1. Mosca L. C-reactive protein--to screen or not to screen? *N Engl J Med* 2002; 347(20):1615-1617.
2. Keys A, Karvonen JM, Punsar S. HDL serum cholesterol and 24-year mortality of men in Finland. *Int J Epidemiol* 1984;13:428-435.
3. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. *JAMA* 1995; 274:131-136.
4. Jousilahti P, Vartiainen E, Pekkanen J, Tuomilehto J, Sundvall J, Puska P. Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland. *Circulation* 1998;97(11):1087-1094.
5. Lichtenstein AH, Kennedy E, Barrier P, et al. Dietary fat consumption and health. *Nutr Rev* 1998;56(5 Pt 2):S3-19.

6. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. *Circulation* 2000; 102(18):2284-2299.
7. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low-density lipoproteins that increase its atherogenicity. *N Engl J Med* 1989;320:915-924.
8. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. *N Engl J Med* 1993;328(20):1450-1456.
9. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and risk of coronary heart disease in women. *N Engl J Med* 1993;328:1444-1449.
10. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342(3):154-160.
11. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345(22):1583-1592.
12. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360(9326):23-33.
13. Kannel WB, Ellison RC. Alcohol and coronary heart disease: the evidence for a protective effect. *Clin Chim Acta* 1996; 246(1-2):59-76.
14. Ellison RC. Cheers! *Epidemiology* 1990;1:337-339.
15. Paffenbarger RS, Jr., Hyde RT, Wing AL, Hsieh C-C. Physical activity, all-cause mortality, and longevity of college alumni. *N Engl J Med* 1986;314: 605-613.
16. Paffenbarger RS, Jr., Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. *N Engl J Med* 1993; 328(8):538-545.
17. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. *N Engl J Med* 1993; 329:1677-1683.
18. Mittleman MA, Siscovick DS. Physical exertion as a trigger of myocardial infarction and sudden cardiac death. *Cardiol Clin* 1996;14(2):263-270.
19. Blair SN, Kampert JB, Kohl HW, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. *JAMA* 1996;276(3):205-210.
20. Expert Panel. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults*. [1]. 1998. Bethesda, MD, Public Health Service, NIH, NHLBI.
21. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. *JAMA* 1999; 282(16):1519-1522.
22. Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. *Arch Intern Med* 1999; 159(10):1104-1109.
23. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the framingham experience. *Arch Intern Med* 2002;162(16):1867-1872.
24. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. *Lancet* 1999;353(9147):89-92.
25. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA* 1998;279(18): 1477-1482.
26. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. *N Engl J Med* 1995; 332(10): 635-641.
27. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000;342(12):836-843.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation* 1998;97(5):425-428.
29. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. *Circulation* 1998;97(20):2007-2011.
30. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med* 2002; 347(20):1557-1565.
31. Rost NS, Wolf PA, Kase CS, et al. Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study. *Stroke* 2001; 32(11):2575-2579.
32. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003;107(3):499-511.
33. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. *N Engl J Med* 1984;310:341-346.
34. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? *Arch Intern Med* 2000;160(4):422-434.
35. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 2002; 288(16):2015-2022.
36. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med* 1999;340(19):1449-1454.
37. Bostom AG, Gohh RY, Liaugaudas G, et al. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid. *Atherosclerosis* 1999;145(1):221-224.
38. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. *Ann Intern Med* 2001;135(2):133-137.
39. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 1990; 82:495-506.
40. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. *Clin Chem* 1992;38(9): 1632-1638.
41. Reaven GM, Abbasi F, Bernhart S, et al. Insulin resistance, dietary cholesterol, and cholesterol concentration in postmenopausal women. *Metabolism* 2001;50(5):594-597.
42. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA* 1996;276(11):875-881.
43. Lamarche B, St Pierre AC, Ruel IL, Cantin B, Dagenais GR, Despres JP. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. *Can J Cardiol* 2001; 17(8):859-865.
44. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). *Clin Chem* 2000;46(12): 1956-1967.
45. Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and Coronary Heart Disease Risk. *Curr Cardiol Rep* 1999;1(2):105-111.
46. Gidding SS, Liu K, Bild DE, et al. Prevalence and identification of abnormal lipoprotein levels in a biracial population aged 23 to 35 years (the CARDIA Study). The Coronary Artery Risk Development in Young Adults Study. *Am J Cardiol* 1996;78(3):304-308.
47. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. *JAMA* 1994;271:999-1003.
48. Scanu AM. Lp(a) lipoprotein – coping with heterogeneity. *N Engl J Med* 2003;349(22):2089-2090.
49. American Heart Association. Heart Disease and Stroke Statistics--2003 Update. American Heart Association. 2002.
50. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285(19):2486-2497.

51. Scanu AM. Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications. *Curr Atheroscler Rep* 2003;5(2):106-113.
52. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002;287(3):356-359.
53. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;24(4):683-689.
54. Lakka HM, Laaksonen DE, Lakka TA, et al. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. *JAMA* 2002;288(21):2709-2716.
55. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation* 2003;108(4):414-419.
56. Nabel EG. Cardiovascular disease. *N Engl J Med* 2003; 349(1):60-72.
57. Breslow JL. Genetic markers for coronary heart disease. *Clin Cardiol* 2001; 24(7 Suppl):II-7.
58. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AB. Hyperlipidemia in coronary heart disease I. Lipid levels in 500 survivors of myocardial infarction. *J Clin Invest* 1973;52:1533-1543.
59. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. *J Lipid Res* 1992; 33:447-454.
60. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA* 1994;272(21):1666-1671.
61. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease on late onset families. *Science* 1993; 261:921-923.
62. Luc G, Bard J-M, Arveiler D, Evans A, et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: The ECTIM Study. *Arterioscler Thromb* 1994;14:1412-1419.
63. Wilson PWF, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. *N Engl J Med* 1997;337(8):516-522.
64. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SKJ. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med* 1999;340(1):14-22.
65. Raggi P, Callister TQ, Cooil B, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. *Circulation* 2000;101(8):850-855.
66. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. *Am Heart J* 2001; 141(3):375-382.
67. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. *Am J Epidemiol* 2002;156(9):871-881.
68. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: The Framingham Study. *Am Heart J* 1984;108:1347-1352.
69. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. *Kidney Int* 1999;56(6):2214-2219.
70. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317(7160):703-713.
71. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? *Am J Kidney Dis* 1998; 32(5):853-906.




Peter W. F. Wilson, MD, graduated with a B.Sc. from Yale University in 1970 and a medical degree from the University of Texas Medical School at San Antonio in 1974. His medical training took place at Duke University and he is board certified in internal medicine and endocrinology. From 1978 to 1999 he was affiliated with the National Heart, Lung, and Blood Institute and from 1983 to 2003 was Director of Laboratories at the Framingham Heart Study. He was a Professor of Medicine on the full-time faculty of the Boston University School of Medicine from 1999-2003 and in 2003 moved to the Medical University of South Carolina, where he is Program Director of the General Clinical Research Center. He has a long-term interest in metabolic and cardiovascular population research. He is an author or coauthor of more than 350 scientific articles and four books.



B W H

Harvard Medical School
 Department of Continuing Medical Education
 and
 The Department of Medicine
 Brigham and Women's Hospital
 present



The 27th Annual Intensive Review of Internal Medicine

July 11-18, 2004
Westin Hotel, Copley Place
Boston, Massachusetts

Course Directors:
 Victor J. Dzau, MD Robert I. Handin, MD
 Ajay K. Singh, MD

*To register or view course information online,
 please visit our home page:*
www.cme.hms.harvard.edu
<http://www.bwhirim.net>

For more information regarding registration:
 Tel: (617) 384-8600 Monday-Friday, 10 am to 4 pm EST
 Fax: (617) 384-8686
 Email: hms-cme@hms.harvard.edu
 Mail: Harvard MED-CME, P.O. Box 825,
 Boston, MA, 02117-0825

Course Fees (Before May 1, 2004)

Full fee with special luncheons and dinner:	\$1,385 (U.S.)
Full fee, Course only:	\$1,145 (U.S.)
Residents/ FIT with special luncheons and dinner:	\$1,140 (U.S.)
Residents/ FIT, Course only:	\$895 (U.S.)

Brigham and Women's Hospital,
 Cardiovascular Division website:
www.heartdoc.org

This publication is made possible by an educational grant from
Novartis Pharmaceuticals Corporation

© 2004 Brigham and Women's Hospital, Boston, Massachusetts, which is solely responsible for the contents. The opinions expressed in this publication do not necessarily reflect those of the publisher or sponsor, but rather are those of the author based on the available scientific literature. Publisher: **SNELL Medical Communication Inc.** in cooperation with Brigham and Women's Hospital, Boston, Massachusetts. TM*Cardiology Rounds* is a Trade Mark of **SNELL Medical Communication Inc.** All rights reserved. The administration of any therapies discussed or referred to in *Cardiology Rounds* should always be consistent with the recognized prescribing information as required by the FDA. **SNELL Medical Communication Inc.** is committed to the development of superior Continuing Medical Education.